Objective: Whole genome sequencing and the screening of 103 families recently led us to identify PRRT2 (proline-rich-transmembrane protein) as the gene causing infantile convulsions (IC) with paroxysmal kinesigenic dyskinesia (PKD) (PKD/IC syndrome, formerly ICCA). There is interfamilial and intrafamilial variability and the patients may have IC or PKD. Association of IC with hemiplegic migraine (HM) has also been reported. In order to explore the mutational and clinical spectra, we analyzed 34 additional families with either typical PKD/IC or PKD/IC with migraine.
There is a long known relationship between human epilepsies and other paroxysmal brain disorders, such as migraine, episodic ataxia, or paroxysmal dyskinesia-the occurrence of involuntary movements, whether spontaneous or triggered by various types of stimuli. Evidence for shared pathophysiologic mechanisms underlying the concurrence of benign infantile convulsions (IC) and of paroxysmal kinesigenic dyskinesia (PKD) in the same patients or families was obtained more than 15 years ago. 1, 2 This defined the autosomal dominant PKD/IC syndrome, 3 formerly known as ICCA (infantile convulsions and paroxysmal choreoathetosis, MIM 602066). 1 IC (or benign infantile seizures) are nonfebrile seizures with onset between 3 and 12 months of age and have a favorable outcome. Patients may develop PKD later in life. In PKD/IC families, individuals who inherited the disease haplotypes had PKD, IC, or both. Linkage of pure autosomal dominant IC at the same genetic 16p12-q12 locus was obtained. 4 Familial association of IC with hemiplegic migraine (HM) has also been reported. 5 Mutations in the PRRT2 gene were very recently identified via exome or whole genome sequencing in PKD [6] [7] [8] and in PKD/IC and IC patients and families. 9, 10 PRRT2 encodes a proline-rich transmembrane protein of unknown function. Interaction with synaptosomal-associated protein 25 (SNAP25) 9 suggests a role in the fusion of synaptic vesicles to the plasma membrane. PRRT2 mutations identified so far include a recurrent and most frequent frameshift mutation (c.649_650insC, p.R217Pfs*8) found in most well-characterized PKD or IC families and in less well-characterized patients or families. [6] [7] [8] [9] [10] Lack of mutant protein expression suggested a loss-of-function mechanism. 9 Altogether, the existence of interfamilial and intrafamilial variability in the phenotypes associated with PRRT2 mutations, and specifically with the most frequent p.R217Pfs*8, raised the question of the possible extension of the mutational and phenotypic spectra. In the present study, the phenotype spectrum was extended to PKD with HM and PRRT2 mutations were also identified in PKD/IC family members with more typical and frequent forms of migraine, and in one sporadic patient having complex migrainous disorder with MRI abnormalities.
METHODS Patients and families. Patients and family members reported in this study gave written informed consent and were all collected according to appropriate ethical guidelines and committees (CPPRB 09/40-n°AC-2008-438/n°DC-2009-1002). A subset of the families have been previously reported. 4, 11 Inclusion criteria were the variable association of IC (afebrile seizures with onset at age 3-12 months without recognized etiology and with a favorable outcome) with PKD later in life (attacks of involuntary movements, usually of short duration, from seconds to minutes, and precipitated by other sudden movements such as standing up from a sitting position or being startled) (appendix e-1 on the Neurology ® Web site at www.neurology.org). Patients with pure PNKD (paroxysmal nonkinesigenic dyskinesia) or with pure paroxysmal exercise-induced dyskinesia were not included. PKD/ IC families were classified as typical when no other neurologic symptom was found in any of the patients. For those PKD/IC families with various types of migraine (so-called atypical PKD/IC families), the diagnosis and classification of migraine were performed according to consensus guidelines according to the International classification. Apart from the aforementioned symptoms, neurologic workups were normal, including interictal EEGs that were performed in a subset of the patients according to the international 10-20 system. Sanger sequencing. DNA was extracted from whole blood according to standard procedures. The coding exons and the exon-intron boundaries of PRRT2 (Genbank NM_145239, AK292393) were screened for mutations by Sanger sequencing of genomic DNA. In family P2315 where PKD and HM cosegregated (figure 1), the coding exons and the exon-intron boundaries of the 3 known HM genes 12 (ATP1A2: Genbank NM_000702; CAC-NA1A: Genbank NM_000068, NM_023035, NM_001127221, NM_001174080, NM_001127222; SCN1A: Genbank NM_ 006920, NM_001165963, NM_001165964) were also screened. Fifty-microliter PCR reactions were carried out with 80 ng of genomic DNA and 10 pmol of each pair of forward and reverse PRRT2 primers, using AccuPrime GC-Rich DNA Polymerase (Life Technologies). Primer pairs are available upon request. All PCR products were purified and both strands were sequenced at GATC Biotech (http://www.gatc-biotech.com/) and the data were analyzed with the Genalys 3.0 software.
Array comparative genomic hybridization experiment.
Array comparative genomic hybridization experiment was performed on one patient (II-2) from the P2315 PKD/HM family, using a 180K oligonucleotide microarray (SurePrint G3 Human CGH Microarray Kit, 4 x 180K, Agilent Technologies, CA) as previously described. 13 Standard protocol approvals, registrations, and patient consents. All experiments were conducted in accordance with the Declaration of Helsinki and all procedures were carried out with the adequate understanding and written consent of the subjects, and after approval from the appropriate ethical committees (CPPRB 09/40-n°AC-2008-438/n°DC-2009-1002).
RESULTS AND DISCUSSION PRRT2 mutations in typical PKD/IC. The recurrent frameshift and diseasecausing mutation (c.649_650insC, p.R217Pfs*8) was found in 11 typical patients and families. A novel frameshift mutation (c.434delC, p.R145Gfs*31) was detected in family P0114. In total, PRRT2 mutations were found in 12 of 24 (50%) patients or families with typical PKD/IC syndrome (figure 1, table). This is fully consistent with the formerly reported prevalence (52/103) of PRRT2 mutations in PKD/IC. 9 PKD and IC showed variable expression and some individuals were also unaffected carriers. Mutations in noncoding sequences or genomic rearrangements of the PRRT2 gene cannot be excluded in the 12 remaining typical families. In 3 of them, missense variations (c.C413G, p.P138A; c.G687A, p.R229K; c.C836T, p.P279S) were found but did not segregate in other patients (data not shown). Eight of these 12 were pure IC families, where genetic heterogeneity has long been known. 2 PRRT2 mutations in PKD/IC with various types of migraine. The clinical spectrum of the recurrent p.R217Pfs*8 PRRT2 mutation was extended to the syndrome of PKD associated with HM in family P2315 ( figure 2, figure 3, table) . HM is a very rare subtype of migraine that shows sporadic or autosomal dominant inheritance. Mutations in 3 genes (ATP1A2, CAC-NA1A, SCN1A) explain about 3/4 of familial patients and a minority of sporadic patients. 12 One ATP1A2 mutation has also been found in a family with IC and HM. 5 In the P2315 PKD/HM family having the recurrent PRRT2 mutation, neither a mutation in the 3 aforementioned HM genes nor a pathogenic genomic alteration were detected by Sanger sequencing and by array CGH, respectively (data not shown). The variation in phenotype between families with the same PRRT2 mutation emphasizes the clinical and genetic links between PKD, IC, and HM. How p.R217Pfs*8 causes the broad and variable phenotype of pure PKD, pure IC, mixed PKD/IC, and mixed PKD/HM is thus far unknown. The genetic defects reported so far in PKD/IC and in HM, and in PNKD, may all lead to altered synaptic functioning. 9, 14 The recurrent p.R217Pfs*8 mutation was detected in another family (P4604) in 3 patients with PKD and migraine without aura (figure 2). One more patient in this family (II-3) who experienced migraine without aura did not inherit the mutation; he did not have PKD and might well be a phenocopy (overall prevalence of migraine is 6% in males). p.R217Pfs*8 was also found in one patient (family P0111) who had IC and migraine with visual aura and with transient speech difficulties. In addition, pR217Pfs*8 was detected in one patient (PKD/IC family P0113) having PKD and reporting migraine without aura. The previously reported p.R240X (c.C719T) nonsense mutation 9 was also found in one family (P0115) member having PKD and migraine without aura. A novel PRRT2 frameshift mutation (c.742delC, p.S248Afs*65) was found in 3 patients (family P0116-12): one had IC only, the other had PKD and GTCS, and the third had IC and migraine with visual and aphasic aura. This and the other novel p.R145Gfs*31 mutation mentioned above were absent from current databases (1000 genomes database, NCBI SNP database) and from an additional series of 95 (p.R145Gfs*31) and 200 (p. S248Afs*65) control individuals of same ethnic origin.
The detection of PRRT2 mutations in 6 PKD/ICrelated families with different forms of migraine including the very rare hemiplegic type, the well-known links between IC and HM, and the increased risk of migraine in PNKD patients (Ptá cek, unpublished data) argue in favor of a nonspurious association of typical migraine in the context of familial PKD/IC with PRRT2 mutations. Indeed, the proportion of migraineurs among PRRT2 mutation carriers (10/ 37) was significantly increased as compared with the overall migraine prevalence (z12%) (p 5 0.02, 2-tailed binomial test). This was even highly significant when only the male carriers were considered (7/19 carriers vs z6% in general population, p 5 0.00015, 2-tailed binomial test). The link between PRRT2 and migraine was also further strengthened by an independent study where PRRT2 mutations are also found in several PKD families with various types of migraine, including the rare hemiplegic type (Gardiner et al., unpublished) . That PRRT2 might participate indifferent migraine types is not surprising, given the previously reported overlaps between HM, migraine with aura, and migraine without aura, 12, 16 on the one hand, and the paroxysmal characteristics shared by the other PRRT2-related brain disorders on the other hand. To further evaluate the spectrum of PRRT2 mutations, we screened a cohort of 49 patients with various types of migraine. The recurrent and disease-causing p.R217fs*8 mutation was detected in one woman (patient DL93) with type I diabetes and having migraine that started at age 48 years with complex sensitive aura (left hemifacial anesthesia), auditory aura (tinnitus), and swallowing difficulties; she had MRI abnormalities consisting of nodular hypersignals in the periventricular white matter (data not shown). Of note, she had no family history of PKD or IC. In this study, the spectrum of PRRT2 mutations was expanded to 2 novel mutations: p.R145Gfs*31 and p.S248Afs*65. Twelve other PRRT2 mutations, including the 2 that were also found here (p.R217fs*8, p.R240X), had been reported so far 6-10 ( figure 3) . The 2 novel mutations detected here are frameshift and, in line with other PRRT2 mutations including the recurrent p.R217fs*8, are thus likely to cause loss of function. The remarkable interfamilial and intrafamilial pleiotropy seen in patients with various PRRT2 mutations might depend on a complex interplay between a given mutant allele, the genetic background of each individual including genes with synaptic functions, the neighboring genomic context, 13 and the influence of nongenetic factors. Our study also extends the phenotypic spectrum of PRRT2 mutations to HM and to other migraine subtypes in the context of PKD/IC families. The recurrent PRRT2 mutation was also detected in one sporadic migraineur with abnormal MRI. A further search for PRRT2 mutations in pure HM and in much larger cohorts of patients with more frequent types of migraine will be of great interest. Overall our data add novel insights into the multiple and somehow uncharacterized relationships existing between various paroxysmal brain disorders. 
